PH-790 Adoptive Cell Transfer T cell therapy(Phio pharmaceuticals)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NamePH-790 Adoptive Cell Transfer T cell therapy(Phio pharmaceuticals)

Drug Alias NameN/A

ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy

Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityProgrammed death-ligand 1 blockers

TargetsProgrammed death-ligand 1

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAphios Corporation

China Registration ClassN/A

Develop Information

Active CompaniesAphios Corporation

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A